Alleviant ALV1 System
DeviceCreation of interatrial shunt
NCT Number: NCT05685303
Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFpEF/HFmrEF.
Interested in participating?
Request Info40 year and older
All sexes
Interventional
Not applicable
Monash Health Victorian Heart Hospital, Clayton, Victoria, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Creation of interatrial shunt
Cardiac imaging
Time frame: 12-month
The primary endpoint is a composite of mortality, heart failure events and quality of life based on Kansas City Cardiomyopathy Questionnaire (KCCQ) calculated at 12 months. KCCQ responses are provided along a rating scale from 0-100 with a higher score indicating better health.
Alleviant Medical, Inc.
Industry
Safety and Efficacy of the Alleviant System for No-Implant Interatrial Shunt Creation in Patients With Chronic Heart Failure
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06280820
Cardiovascular Diseases, Heart Diseases
Falls Church, Virginia, United States
View Trial DetailsNCT07730268
Cardiovascular Diseases, Disease
Long Beach, California, United States
View Trial DetailsNCT05791227
Cardiovascular Diseases, Heart Diseases
Los Angeles, California, United States
View Trial DetailsNCT05086978
Cardiovascular Diseases, Heart Diseases
Cleveland, Ohio, United States
View Trial Details